Y-Mabs Therapeutics Inc (YMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Sales | 19,931 | 23,363 | 20,454 | 20,751 | 20,251 |
| Cost of Goods | 2,097 | 2,039 | 2,595 | 4,649 | 2,083 |
| Gross Profit | 17,834 | 21,324 | 17,859 | 16,102 | 18,168 |
| Operating Expenses | 24,839 | 24,562 | 26,203 | 23,974 | 25,752 |
| Operating Income | -6,908 | -3,199 | -7,749 | -7,223 | -7,501 |
| Other Income | 439 | 2,406 | 189 | 1,100 | 1,111 |
| Pre-tax Income | -6,469 | -793 | -7,560 | -6,123 | -6,390 |
| Income Tax | 160 | 195 | 187 | 179 | N/A |
| Net Income Continuous | -6,629 | -988 | -7,747 | -6,302 | -6,390 |
| Net Income | $-6,629 | $-988 | $-7,747 | $-6,302 | $-6,390 |
| EPS Basic Total Ops | -0.15 | -0.02 | -0.18 | -0.14 | -0.15 |
| EPS Basic Continuous Ops | -0.15 | -0.02 | -0.18 | -0.14 | -0.15 |
| EPS Diluted Total Ops | -0.15 | -0.02 | -0.18 | -0.14 | -0.15 |
| EPS Diluted Continuous Ops | -0.15 | -0.02 | -0.18 | -0.14 | -0.15 |
| EPS Diluted Before Non-Recurring Items | -0.15 | -0.02 | -0.18 | N/A | N/A |
| EBITDA(a) | $-6,749 | $-3,038 | $-7,581 | $-6,999 | $-7,319 |